Staphylococcus Aureus
Conditions
Brief summary
In this clinical trial we will test a new approach for decolonization of S. aureus. As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned.
Interventions
DRUGHY_133
A recombinant chimeric bacteriophage endolysin HY-133
DRUGPlacebo
Placebo
Sponsors
University Hospital Tuebingen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Must be ≥ 18 years at the time of signing the informedconsent. * Understand and voluntarily sign an informed consent document prior to any study related * assessments/procedures. * Nasal colonization with methicillin-susceptible S. aureus (MSSA) * Female Subject of childbearing potential1 and male subjects with female partner of childbearing potential1 is willing to use highly effective contraceptive methods during treatment until end of study at D15
Exclusion criteria
* Nasal colonization with methicillin-resistant S. aureus (MRSA) * Nasal traumata including nose penetrating foreign bodies (e.g. piercings) * Presence of any significant morbidity, e.g. Diabetes, cardiovascular disease * Acute or known chronic diseases of the nose or the paranasal sinuses * Acute or known chronic diseases of other parts of the respiratory tract * Running nose due to other reasons (e.g. allergic diseases)7. Positive serological HIV, hepatitis A, B or C test. In case of positive HBsAg, volunteer must provide prove of hepatitis B vaccination, otherwise volunteer must be excluded. * Women during pregnancy and lactation. * History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * Participation in other clinical trials or observation period of competing trials, in the 12 weeks prior to screening. * Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the Investigator based on medical history, physical exam, and/or laboratory screening test * Systemic antibiotic treatment in the 12 weeks prior to screening. * Intranasal eradication therapy in the 12 weeks prior to screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ADRs/AEs/SAEs occurring from the time of application until the final study visit (Day15) for each subject | baseline, pre-intervention/procedure/surgery, up to Day15 | The primary objective of this trial is to evaluate the safety of the HY-133. Fort the primary objective the nature, frequency, and severity of AEs and/or SAEs occurring in the study are recorded as follows: ADRs/AEs/SAEs occurring from the time of application until the final study visit (D15) for each subject A DLT is defined as any AE of Grade 4 or above related to the IMP |
Countries
Germany
Contacts
Primary ContactSebastian Volc, PD
Outcome results
None listed